Endo Pharmaceuticals today announced that the FDA has approved Felodipine Extended-release tablets USP, 2.5mg, 5mg and 10mg.  Qualitest Pharmaceuticals, the generic business unit of Endo Pharmaceuticals, will manufacture and distribute the Felodipine Extended-release tablets.

Felodipine Extended-release tablets USP are the generic version of AstraZeneca’s Plendil Extended-release tablets.

The total sales for Felodipine in the U.S. for the 12 months ended June 30, 2011 were approximately $84 million, according to IMS Health.